Caroline F Pratz

The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

E. Antonarakis, R. Brodsky, J. C. Park, 2015, Clinical genitourinary cancer.

Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care.

V. Sinibaldi, Caroline F Pratz, Olga Yankulina, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.

Jun Luo, E. Antonarakis, M. Carducci, 2020, European journal of cancer.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

C. Drake, Jun Luo, E. Antonarakis, 2018, The Lancet. Oncology.

Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.

Caroline F Pratz, Frank dela Rama, 2015, Clinical journal of oncology nursing.

Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).

Jun Luo, E. Antonarakis, M. Carducci, 2017 .